Roche Just Kicked Down Illumina's Front Door
Roche launched its AXELIOS 1 gene sequencer, pricing genomes at $150 and taking direct aim at Illumina's decade-long grip on the sequencing market. With 13 years of failed attempts behind it, Roche's comeback is backed by new chemistry, heavyweight partnerships, and pricing that could reshape genomic medicine.
For over a decade, Illumina has owned gene sequencing the way Google owns search. Competitors existed, sure. But nobody with real scale, real money, and a real grudge had stepped into the ring. Until now.
On June 29, Roche launched AXELIOS 1, a next-generation gene sequencer built on entirely new chemistry. The roughly $260 billion Swiss pharma giant isn't tiptoeing into the market with a niche product. It's aiming a $750,000 machine directly at Illumina's core business: reading the human genome faster and cheaper than anyone else.
This isn't Roche's first attempt. It's a revenge tour.
The Grudge Match Nobody Saw Coming
Roche and gene sequencing have a complicated history. Think of it like an ex who keeps showing up at your door with increasingly elaborate apologies.
In 2005, Roche partnered with a pioneering sequencing company called 454 Life Sciences, then bought it outright in 2007 for about $155 million. The technology looked promising, but 454's platform couldn't keep up with Illumina's relentless improvements. By 2013, Roche pulled the plug and shut down 454 entirely.
Between those two events, Roche tried something even bolder: a hostile takeover bid for Illumina itself in 2012. Illumina fought it off. Roche walked away empty-handed.
So what did Roche do? It went shopping. It acquired Genia Technologies (nanopore sequencing), invested in bioinformatics through Bina Technologies ($114 million), and in 2020 bought Stratos Genomics. Stratos developed something called "sequencing by expansion," or SBX. That chemistry is the engine inside the AXELIOS 1.
Thirteen years of acquisitions, failures, and billions of dollars later, Roche is back. And this time, it brought receipts.
What Makes AXELIOS Different
The core technology works like this: SBX converts DNA and RNA into stretched-out molecules called Xpandomers (think of uncoiling a Slinky so you can read each ring individually). Those expanded molecules pass through millions of tiny nanopores on a reusable sensor chip. The machine reads each one in real time.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
